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Objective: Patellofemoral joint osteoarthritis (PFJ OA) contributes considerably to knee OA symptoms.
This study aimed to determine the efﬁcacy of a PFJ-targeted exercise, education manual-therapy and
taping program compared to OA education alone, in participants with PFJ OA.
Methods: A randomised, participant-blinded and assessor-blinded clinical trial was conducted in
primary-care physiotherapy. 92 people aged 40 years with symptomatic and radiographic PFJ OA
participated. Physiotherapists delivered the PFJ-targeted exercise, education, manual-therapy and taping
program, or the OA-education (control condition) in eight sessions over 12 weeks.
Primary outcomes at 3-month (primary) and 9-month follow-up: (1) patient-perceived global rating of
change (2) pain visual analogue scale (VAS) (100 mm); and (3) activities of daily living (ADL) subscale of
the Knee injury and Osteoarthritis Outcome Score (KOOS).
Results: 81 people (88%) completed the 3-month follow-up and data analysed on an intention-to-treat
basis. Between-group baseline similarity for participant characteristics was observed. The exercise, ed-
ucation, manual-therapy and taping program resulted in more people reporting much improvement (20/
44) than the OA-education group (5/48) (number needed to treat 3 (95% conﬁdence interval (CI) 2 to 5))
and greater pain reduction (mean difference: 15.2 mm, 95% CI 27.0 to 3.4). No signiﬁcant effects on
ADL were observed (5.8; 95% CI 0.6 to 12.1). At 9 months there were no signiﬁcant effects for self-report
of improvement, pain (10.5 mm, 95% CI 22.7 to 1.8) or ADL (3.0, 95% CI 3.7 to 9.7).
Conclusion: Exercise, education, manual-therapy and taping can be recommended to improve short-term
patient rating of change and pain severity. However over 9-months, both options were equivalent.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12608000288325): https://
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id¼82878.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Patellofemoral joint osteoarthritis (PFJ OA) remains an under-
recognized category of arthritis. Evident in almost 70% of adults




ternational. Published by Elsevier LOA1e3,5,6. Patellofemoral OA is observed early in the trajectory of
knee OA disease process7, and is observed in 55% of people aged
under 50 years3. Since the PFJ contributes more to the symptoms of
knee OA than the TFJ4,8,9, PFJ OA can adversely affect quality of life,
economic productivity and daily function in younger adults with
critical career and childcare responsibilities.
Clinical guidelines prioritise conservative (non-pharmacolog-
ical) treatments as a ﬁrst line knee OA management and recom-
mend tailoring treatments to the location of joint damage10e12 (i.e.,
to the PFJ compartment for individuals with PFJ OA). Many trials
have evaluated physical therapies for patients with predominantlytd. All rights reserved.
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of exercise and manual-therapy applied to those with predominant
TFJ OA14,15, supporting the recommendation for targeted in-
terventions. Only two clinical trials speciﬁcally assessed treatments
for PFJ OA, with no positive effects reported for either combined
exercise therapy with patellar taping16 or patellofemoral bracing17.
The lack of beneﬁt may reﬂect the lack of tailoring of exercise and
patellar taping to the individual16,17 or the use of a single treatment
component (bracing)17.
The Consensus Statement from the Third International Patello-
femoral Research Retreat18 suggested a disease continuum that
manifests as PFJ pain in younger adults and PFJ OA at later
stages19,20. Common impairments include patellar
malalignment21e23, quadriceps and hip muscle weakness24e29. This
provides a rationale to consider treatments designed for PFJ pain in
younger adults for older people with PFJ OA. Our previous clinical
trials proved the effectiveness of quadriceps and hip muscle
retraining exercises, patellar taping, and patellar mobilisation for
PFJ pain in younger adults30,31.
We aimed to evaluate whether a PFJ-targeted program that
combined (1) exercise, (2) education, (3) manual therapy and (4)
taping, results in greater improvements in patient rated change,
pain and physical function than physiotherapist-delivered OA ed-
ucation in participants with symptomatic and radiographic PFJ OA.
We hypothesised that the PFJ-targeted program of exercise, edu-
cation, manual-therapy and taping would be superior to the OA-




We conducted a randomised, assessor- and participant-blinded
controlled clinical trial, as described previously32. The trial was
prospectively registered in the Australian New Zealand Clinical
Trials Registry (ACTRN12608000288325). The study had ethical
approval (HREC number: 0721163) and all participants provided
written informed consent prior to commencement, and all human
testing procedures undertaken conformed to the standards of the
Declaration of Helsinki.
Setting and participants
The clinical trial was conducted in primary care physiotherapy
practices. Volunteers from the greater Melbourne (Australia) area
responded to advertisements in print and radio media, posters in
sporting clubs, health and medical practices and referrals from
practitioners. Potential participants underwent telephone
screening, followed by a physical screening by an experienced
physiotherapist and standardised weight-bearing semi-ﬂexed,
standing, posteroanterior and skyline radiographs to assess the
severity of TFJ and PFJ OA.
To be included, volunteers were required to be aged at least 40
years; have anterior or retro-patellar pain that was aggravated by
two or more PFJ-loaded activities (e.g., stair ambulation, rising from
sitting or squatting); have an average pain score of at least 3 on an
11-point scale (0 ¼ no pain; 10 ¼ worst pain possible) during
aggravating activities and onmost days during the past month; and
have evidence of lateral PFJ osteophytes33 on weight-bearing
skyline radiographs34. Participants were excluded if they had pain
from other lower-limb sites; predominantly TFJ joint symptoms on
clinical examination (e.g., location of pain, tenderness on palpa-
tion); current or previous (prior 12 months) physiotherapy for knee
pain; recent knee injections (prior 3 months); previous or planned(following 6 months) knee surgery; physical inability to undertake
testing; other medical conditions; inability to understand written
and spoken English; and a body mass index (BMI) greater than
34 kg m2. Additionally, individuals with medial >lateral PFJ
osteophytes or moderate-to-severe concomitant TFJ OA (Kellgren
and Lawrence35 grade >2) were excluded.
Randomisation and interventions
The randomisation sequence (computer-generated permuted
blocks of 8e12) was generated a priori and kept external (Univer-
sity of Queensland) to the administration site (University of Mel-
bourne) by an independent investigator. Participants were
randomly allocated to either exercise, education, manual-therapy
and taping or OA-education and were informed that two types of
physiotherapist-delivered treatments were being compared, but
the types of intervention and study hypotheses were concealed. A
research assistant, not involved in outcome assessment, revealed
the allocation to the physiotherapist delivering the intervention
following baseline assessment and prior to the ﬁrst appointment.
Each participant attended the private practice of one of eight
trained project physiotherapists, at various Melbourne metropol-
itan sites. Physiotherapists were experienced in treating patients
with knee and PFJ conditions and underwent 6 h of training (with
KMC) to standardise the treatment elements and their prescription,
as described in the published protocol32. Physiotherapists provided
both the active and control interventions and thus were not blinded
to group allocation. Eight treatments (approximately 60 min
duration) were provided once a week for 4 weeks and then once
every 2 weeks for 8 weeks for each group. The interventions have
been described in detail previously32.
The PFJ-targeted exercise, education, manual-therapy and tap-
ing programwas standardised to consist of (1) functional retraining
exercises for the quadriceps and hip muscles; (2) quadriceps and
hip muscle strengthening; (3) patellar taping; (4) manual-therapy
(PFJ, TFJ and soft tissue mobilisation); and (5) OA-education
(Supplementary Table). The standard elements of the treatment
were then tailored, such that each participant's clinical presenta-
tion (e.g., strength, pain severity, swelling) as well as the presence
of co-morbidities (e.g., back and hip pain or pathology) were taken
into consideration, and exercises were chosen and progressed by
the physiotherapist based on each participant's response to exer-
cise load. This approach ensured that the highest level of load could
be applied, whilst keeping the participant's pain to a minimal level
(2 on a 0e11 numerical rating scale). Exercises were taught and
supervised by the physiotherapist during each visit with a home
exercise program prescribed, to be performed independently at
home four times per week. An exercise manual was provided for
participants with clear instructions and diagrams to ensure correct
and safe performance of all exercises. At the completion of the 3-
month intervention period and outcome assessment, participants
were encouraged to continue with their home exercise program.
The OA-education intervention (control group) was a
physiotherapist-delivered series of single-patient sessions,
designed to control for the patientetherapist interaction and psy-
chosocial contact inherent with the PFJ-speciﬁc physiotherapy
intervention. The information was obtained from the Arthritis
Victoria patient information sheets (http://www.arthritisvic.org.
au), and at each session different topics were discussed (1): intro-
duction to OA; (2): maintaining physical activity; (3): medicines;
(4): complementary therapies; (5): healthy eating; (6) dealing with
chronic pain; (7): emotions and depression and (8): summary,
revision of key concepts.
Participants in both groupswere encouraged to continue regular
physical activity that did not provoke their pain. The use of
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counter medicines) were permitted and recorded in weekly log
books.
Outcome measurements
A blinded examiner administered all outcome measures. In
those with bilateral symptoms, the most symptomatic eligible knee
was assessed. Participant characteristics were recorded at baseline.
The principal time-point for efﬁcacy analyses was at treatment
completion (3 months), with a secondary follow-up time-point
included after 6 months of no treatment to assess maintenance of
effects (9 months).
Primary outcomes were patient-perceived global rating of
change (from baseline) on a 5 point Likert scale (5 ¼ much worse;
4 ¼ worse; 3 ¼ same; 2 ¼ improved; 1 ¼ much improved)30, knee
pain severity during an aggravating activity on a 0e100 mm visual
analogue scale (VAS)32 and the activities of daily living (ADL)
subscale of the Knee injury and Osteoarthritis Outcome Score
(KOOS)36. The KOOS-ADL subscale is identical to the physical
function subscale of the Western Ontario and McMasters Univer-
sities Osteoarthritis Index (WOMAC)37, and a normalised score was
calculated (100 represents no symptoms and 0 represents
maximum symptoms). Secondary outcome measures included the
pain, symptoms, sport and recreation and quality-of-life subscales
of the KOOS. Adherence was measured from attendance at phys-
iotherapy and completion of home exercise log books. Adverse
events and medication use were recorded in log books. Partici-
pants were considered to be adherent with the home exercises if
they completed three of the required four times per week (i.e.,
75%).
Sample size
Based on our previous RCT of PFJ-targeted physiotherapy for PFJ
pain31, we required 38 people per group to detect 49% of people in
the physiotherapy group reporting much improvement on the
global rating of change, compared with 19% of people in the edu-
cation group, with 80% power (a ¼ 0.05). A sample size of 90 also
enabled detection of the minimal clinically important improve-
ments of 19.9 (21.5) mm on a 100 mm pain VAS and 9.1 (13.9)
normalised units on theWOMAC physical function subscale38, with
90% power (a ¼ 0.05) and accounting for approximately 10%
dropouts.
Statistical analysis
All analyses were performed with SPSS for Windows 21.0
software (SPSS, Chicago, IL, USA), conducted on an intention-to-
treat basis. Global rating of change was dichotomised as no suc-
cess (much worse, worse, same, moderate improvement) and
success (marked improved), and expressed as relative risk reduc-
tion and Numbers Needed to Treat (NNT). Worst-case scenario
imputation of missing values was performed, with targeted
physiotherapy assigned much worse and OA-education assigned
much improved. We analysed continuous outcome measures using
linear mixed regression models, including their respective baseline
scores as a covariate, participants as a random effect, treatment
condition as a ﬁxed factor and the covariate by treatment inter-
action. Analyses were repeated with participant characteristics
(age, gender, BMI and radiographic disease severity) included as
covariates to evaluate their impact. Regression diagnostics were
used to check for normality of the measures and homogeneity of
variance, where appropriate. Statistical signiﬁcance was set at
P ¼ 0.05.Results
Between August 2008 and December 2010, 365 people vol-
unteered to participate in the study. In total, 92 people (Fig. 1)
fulﬁlled the eligibility criteria and were randomised to the PFJ OA-
targeted exercise, education, manual-therapy and taping protocol
(n ¼ 44) and OA-education control (n ¼ 48) groups; 81 people
completed the 3-month follow-up (39 physiotherapy and 42 OA-
education; 88%) and 73 people completed the 9-month follow-up
(35 physiotherapy and 38 OA-education; 79%). The two groups
were similar at baseline for all participant characteristics (Table I).
The characteristics of the 11 participants lost to follow-up were not
different to those who completed the study.
Primary outcomes
The exercise, education, manual-therapy and taping resulted in
more people being much improved (20/44) than the OA-education
group (5/48) at 3-months (relative risk 4.31; 95% conﬁdence in-
terval (CI): 1.79e10.36; NNT 3 (95% CI: 2e5) (Fig. 2)). The worse-
case scenario imputation of missing values, with the exercise, ed-
ucation, manual-therapy and taping intervention assigned much
worse and the OA-education assigned much improved, did not
change the outcome substantially or statistically beyond 0.05.
People in the combined exercise, education, manual-therapy and
taping group reported signiﬁcantly greater reductions in pain than
those in the OA-education group (mean difference: 15.2 mm, 95%
CI: 27.0 to 3.4). However, there were no signiﬁcant effects on
physical function as measured using the KOOS-ADL
(5.8; 0.6e12.1). Including age, gender, BMI and radiographic dis-
ease severity as covariates did not affect the outcomes and hence,
the unadjusted data are presented (Table II).
Secondary timepoint (9 months)
At 9-months, more people in the exercise, education, manual-
therapy and taping group than in the OA-education group re-
ported being much improved (relative risk 3.26 (95% CI 1.46e7.26);
NNT 3 (95% CI 2e7)) (Fig. 2). However, imputing missing data (21%)
on a worse-case scenario, the results were no longer statistically
signiﬁcant. No signiﬁcant between-group differences were
observed for participant-reported knee pain (10.5 mm; 95%
CI 1.8e22.7), KOOS-ADL (3.0; 95% CI 3.7e9.7).
Secondary outcomes
At 3-months, the exercise, education, manual-therapy and tap-
ing intervention and the OA-education control resulted in similar
outcomes for all secondary outcome measures (Table III) except for
KOOS-pain, where those in the exercise, education, manual-
therapy and taping group reported signiﬁcantly greater re-
ductions in KOOS-pain than those in the OA-education group (6.0;
95% CI 0.1e12.6). After 6-months of no treatment, there were no
signiﬁcant between-group differences (Table III).
Adherence, adverse events, and co-interventions
No signiﬁcant differences were observed between groups for
attendance (mean (SD) number of sessions: Physiotherapy: 8 (2);
OA-education 8 (1)). Log-books for exercise adherence were ob-
tained from 31 (71%) of the participants in the physiotherapy group.
Adherence with home exercises was recorded by 24 (77%) partici-
pants. Adverse events were noted in seven of the participants
receiving the exercise, education, manual-therapy and taping
intervention (skin reaction to tape wearing (n ¼ 2)); swelling after
Fig. 1. CONSORT 2010 Flow Diagram (modiﬁed for individual randomized, controlled trials of non-pharmacologic treatment) Participants lost to follow-up at 3 months were not
followed up at 9 months.
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Table I
Baseline characteristics of participants for Physiotherapy and OA-education groups.
Values are mean (SD) unless stated otherwise
Physiotherapy (n ¼ 44) OA-education (n ¼ 48)
Age (years) 56 (10) 53 (10)
Height (m) 1.69 (0.08) 1.70 (0.10)
Mass (kg) 78 (14) 81 (16)
BMI (m.kg-2) 27.2 (4.0) 27.9 (4.6)
Female gender n (%) 24 (45) 29 (55)
KL grade n (%)
- Grade 0 23 (52) 26 (54)
- Grade 1 11 (25) 9 (18)
- Grade 2 10 (23) 13 (27)
PFJ O/P severity n (%)
- Grade 1 31 (70) 30 (63)
- Grade 2 8 (18) 12 (25)
- Grade 3 5 (12) 5 (10)
V: Physiotherapy n ¼ 42; Control n ¼ 45.
KL Kellgren and Lawrence grading scale35 for the tibiofemoral joint measured from
an anteroposterior radiograph.
PFJ O/P severity: Severity of lateral patellar osteophyte measure from a skyline X-
ray33.
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n ¼ 1; ankle n ¼ 1; other knee n ¼ 1). All adverse events were mild,
did not requiremedical treatment, nor cause cessation of treatment
(some adjustments to taping and/or exercises were made by the
treating physiotherapist). Use of co-interventions, including med-
ications, was similar between groups. In the group undertaking
exercise, education, manual-therapy and taping, medication use
was recorded in 10 people: analgesics (n ¼ 7), non-steroidal anti-
inﬂammatory drugs (n ¼ 4) and glucosamine (n ¼ 2). Similar
medication use was recorded in the OA-education group: analge-
sics (n ¼ 7), non-steroidal anti-inﬂammatory drugs (n ¼ 4),
glucosamine (n ¼ 2) and ﬁsh oil (n ¼ 1).Discussion
Exercises, education, manual-therapy and taping, targeted to
the PFJ resulted in superior outcomes for patient-perceived change
in condition and pain, compared to physiotherapist-delivered OA-Fig. 2. Percentage of participants reporting perceived improvement across categories
from ‘much improved’ to ‘much worse’.education. However physical function was not different between
groups. There were no differences at 9-months.
Our study ﬁlls a gap in the literature, where most evidence ex-
ists for medial TFJ OA. The importance of our targeted intervention
is underpinned by recent recommendations to tailor non-
pharmacological management for knee OA10. Considering that
approximately 70% of people aged above 50 with knee pain with or
without radiographic OA have PFJ involvement, and the differences
between the PFJ and TFJ compartment in joint biomechanics39, risk
factors for disease progression40,41 and symptomatic pre-
sentations27,29,42, a PFJ OA-focussed intervention is appropriate.
Furthermore, people with PFJ OA derive lesser beneﬁts than those
with TFJ OA from a non-speciﬁc exercise therapy14 that does not
consider the unique functional and biomechanical impairments
associated with PFJ OA. Our study shows that three patients with
PFJ OA would need to be treated with our targeted physiotherapy
intervention compared to OA-education, for one person to report a
marked improvement in their condition.
Implications for management of PFJ osteoarthritis
Current management of PFJ OA remains problematic for most
health and medical practitioners due to the lack of trials evaluating
treatments tailored to this condition. Our treatment protocol
addressed shortfalls of previous trials. We included information
and education that addressed pacing of activity and discussion of
weight management. Most importantly, the exercise program
addressed the impairments commonly observed in PFJ OA (quad-
riceps and hip muscle weakness), tailoring the prescription and
progression of exercises to individual abilities and co-morbidities.
Patellar malalignment, a prominent feature of PFJ OA21e23, was
assessed for each individual and addressed with patient-speciﬁc
mobilisations and taping.
The lack of beneﬁt following an additional 6 months of no
treatment might indicate that interventions involving exercise,
education, manual-therapy and taping for this patient population
need to be extended. The targeted physiotherapy group was
instructed to maintain their home exercise programme. However,
the programme was not supervised or progressed over the
following 6 months. Furthermore, adherence to the unsupervised
programme is unknown. Considering that OA is a chronic disease,
our results indicate the need for trials with either an extended
supervised treatment duration, or additional means to ensure
adherence to an unsupervised programme.
This study has a number of important strengths. To facilitate
recruitment of those with predominant PFJ OA, our eligibility
criteria included history, examination and radiographic criteria. The
studied treatment was evidence-based and incorporated recom-
mendations from clinical guidelines. Our comparison group
(physiotherapist-delivered OA-education) controlled for the
patientetherapist interaction inherent within our targeted phys-
iotherapy intervention and sought to reduce performance bias.
Participants and assessors were blinded to treatment allocation, to
reduce the treatment bias and/or response bias. Adherence to the
interventions was high and adverse events were mild.
There are some limitations to our study, with themain one being
a loss of 21% of participants to follow up at 9-months. The worse-
case scenario imputation for missing data implemented in the
analysis lead to a conclusion of no beneﬁt of exercise, education,
manual-therapy and taping over OA education alone. The impact on
the interpretation of the long-term outcomes might undermine the
potentially real beneﬁts of the exercise, education, manual-therapy
and taping, because analysis without worse case scenario imputa-
tion showed a beneﬁcial effect of the education, exercise, manual-
therapy and taping program. While there was a 12% loss of
Table II
Mean (SD) scores for continuous primary and secondary outcomes at baseline, 3 months and 9 months (adjusted for baseline scores), according to group














Knee pain on aggravating
activity (0e100)
58 (26) 58 (27) 29 (28) 45 (31) 33 (30) 44 (29)
KOOS-ADL (100e0) 72.2 (14.9) 70.8 (16.9) 83.8 (12.8) 76.6 (14.6)* 82.1 (14.8) 77.7 (16.0)
Secondary outcomes
KOOS-Pain (100e0) 64.0 (14.7) 63.4 (14.3) 76.3 (13.4) 69.4 (14.2)* 75.5 (16.5) 73.5 (14.4)
KOOS-Symptoms (100e0) 64.5 (14.7) 61.2 (17.5) 74.9 (13.7) 68.7 (17.8)* 74.3 (12.6) 71.6 (18.0)
KOOS-SR (100e0) 42.4 (20.4) 43.4 (21.5) 56.4 (23.3) 48.7 (22.2)* 58.5 (20.7) 53.3 (25.0)
KOOS-QoL (100e0) 44.3 (14.2) 39.5 (15.5) 54.7 (20.0) 49.8 (13.8)* 56 (19.6) 52 (15.2)
Knee pain on aggravating activities measured with a VAS (mm: 100 ¼ maximal pain possible).
KOOS-ADL ¼ ADL subscale of the KOOS (100 ¼ best possible score).
KOOS-Pain ¼ Pain subscale of the KOOS (100 ¼ best possible score).
KOOS-Symptoms ¼ Symptoms subscale of the KOOS (100 ¼ best possible score).
KOOS-SR ¼ Sport and recreation subscale of the KOOS (100 ¼ best possible score).
KOOS-QoL ¼ Quality of Life subscale of the KOOS (100 ¼ best possible score).
* n ¼ 41.
Table III
Estimated between-group differences, adjusted for the baseline value of the mea-
sure (mean difference and 95% CIs), in the change scores from baseline to 3 months
and from baseline to 9 months
Baseline e 3 months Baseline e 9 months
Primary outcomes
Knee pain on aggravating
activity (0e100)
15.2 (27.0 to 3.4)* 10.5 (22.7 to 1.8)
KOOS-ADL (100e0) 5.5 (0.6 to 11.2) 3.0 (3.7 to 9.7)
Secondary outcomes
KOOS-Pain (100e0) 6.0 (0.1 to 12.6)* 1.4 (5.2 to 8.0)
KOOS-Symptoms (100e0) 3.0 (3.1 to 8.9) 0.6 (6.9 to 5.8)
KOOS-SR (100e0) 8.7 (1.2 to 18.6) 6.2 (4.2 to 16.5)
KOOS-QoL (100e0) 0.1 (7.1 to 7.0) 0.9 (8.3 to 6.5)
Knee pain on aggravating activities measured with a VAS (mm: 100 ¼maximal pain
possible).
KOOS-ADL ¼ ADL subscale of the KOOS (100 ¼ best possible score).
KOOS-Pain ¼ Pain subscale of the KOOS (100 ¼ best possible score).
KOOS-Symptoms ¼ Symptoms subscale of the KOOS (100 ¼ best possible score).
KOOS-SR ¼ Sport and recreation subscale of the KOOS (100 ¼ best possible score).
KOOS-QoL ¼ Quality of Life subscale of the KOOS (100 ¼ best possible score).
* denotes statistically signiﬁcant.
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effect of the exercise, education, manual-therapy and taping pro-
gram was still present on imputing missing data on a worst-case
scenario basis. As with other non-pharmacological trials, it is not
possible to blind the physiotherapists providing the treatment.
Furthermore, the results of this trial cannot be extrapolated to those
with different clinical features or patterns of radiographic OA, and
the long-term effects cannot be assumed and should be evaluated.
In conclusion, after 3-months an 8-session multi-modal treat-
ment of exercise, OA education, manual-therapy and taping that
was targeted to the PFJ and tailored to individual patients resulted
in superior outcomes for patient-perceived change and pain
compared to OA-education alone in people with predominant PFJ
OA. However, there was no signiﬁcant difference in physical func-
tion and the positive effects observed after 3 months of treatment
were not maintained after 6 months of no treatment. Conservative
management of PFJ OAmay be enhanced by targeting interventions
to the PFJ compartment.Author's contributions
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